FILE:COV/COV-8K-20090128080008.txt.gz
EVENTS:	Regulation FD Disclosure	Financial Statements and Exhibits
TEXT:
ITEM: Regulation FD Disclosure
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
 
 
 
 
 
On January 28, 2009, Covidien Ltd. issued a press release announcing that its Board of Directors had authorized a program to purchase up to $300 million of the company's common shares from time to time, based on market conditions, to partially offset dilution related to equity compensation plans.
A copy of the press release is furnished as Exhibit 99.1 to this report.
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

Exhibit 99.1
Covidien Declares Quarterly Cash Dividend and Announces Stock Buyback
DUBLIN, Ireland  January 28 2009 - Covidien (NYSE: COV; BSX: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.16 per common share. The dividend is payable on February 27, 2009, to shareholders of record on February 6, 2009.
Covidien also announced that its Board of Directors had authorized a program to purchase up to $300 million of the Company's common shares from time to time, based on market conditions, to partially offset dilution related to equity compensation plans.
ABOUT COVIDIEN LTD.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
 


